Abstract: A method for extracting water-soluble undenatured type II collagen having an active epitope comprises a first step for extracting animal-derived cartilage using an acidic solution at 50° C. or less, and a second step for adding pepsin to the acidic solution and performing extraction at 40° C. or less. This allows the epitope of undenatured type II collagen to be extracted in large quantities and with high efficiency without any loss of activity, and makes it possible to provide a food or beverage product obtained using the water-soluble undenatured type II collagen extracted by the extraction method.

Abstract: It is intended to provide a platelet aggregation inhibitor which can be easily processed into a pharmaceutical preparation and can be stored for a long time, and a health food effective in inhibiting platelet aggregation. The platelet aggregation inhibitor comprises, as an active ingredient, a degradation product obtained by reacting fibrin with nattokinase, wherein the degradation product has a molecular weight of 10,000 daltons or less. The fibrin is obtained by reacting fibrinogen with thrombin.

Abstract: An object of the present invention is to provide a platelet aggregation inhibitor without side effects and a supplement food effective for inhibiting platelet aggregation. The platelet aggregation inhibitor has nattokinase as an active ingredient and has Bacillus natto culture extract, containing a high proportion of nattokinase containing 1 ?g/g or less of vitamin K2 on a dry weight basis, as an active ingredient. The supplement food effective for inhibiting platelet aggregation has nattokinase as an active ingredient and has Bacillus natto culture extract, containing a high proportion of nattokinase containing 1 ?g/g or less of vitamin K2 on a dry weight basis, as an active ingredient.

Abstract: An object of the present invention is to provide a platelet aggregation inhibitor without side effects and a supplement food effective for inhibiting platelet aggregation. The platelet aggregation inhibitor has nattokinase as an active ingredient and has Bacillus natto culture extract, containing a high proportion of nattokinase containing 1 ?g/g or less of vitamin K2 on a dry weight basis, as an active ingredient. The supplement food effective for inhibiting platelet aggregation has nattokinase as an active ingredient and has Bacillus natto culture extract, containing a high proportion of nattokinase containing 1 ?g/g or less of vitamin K2 on a dry weight basis, as an active ingredient.

Abstract: An object of the present invention is to provide a platelet aggregation inhibitor without side effects and a supplement food effective for inhibiting platelet aggregation. The platelet aggregation inhibitor has nattokinase as an active ingredient and has Bacillus natto culture extract, containing a high proportion of nattokinase containing 1 mg/g or less of vitamin K2 on a dry weight basis, as an active ingredient. The supplement food effective for inhibiting platelet aggregation has nattokinase as an active ingredient and has Bacillus natto culture extract, containing a high proportion of nattokinase containing 1 mg/g or less of vitamin K2 on a dry weight basis, as an active ingredient.

Abstract: An object of the present invention is to provide a platelet aggregation inhibitor without side effects and a supplement food effective for inhibiting platelet aggregation. The platelet aggregation inhibitor has nattokinase as an active ingredient and has Bacillus natto culture extract, containing a high proportion of nattokinase containing 1 &mgr;g/g or less of vitamin K2 on a dry weight basis, as an active ingredient. The supplement food effective for inhibiting platelet aggregation has nattokinase as an active ingredient and has Bacillus natto culture extract, containing a high proportion of nattokinase containing 1 &mgr;g/g or less of vitamin K2 on a dry weight basis; as an active ingredient.

Abstract: A material containing a flavonoid glycoside represented by formula I as a major component has an in vivo antiallergic effect, which can be prepared in a large amount with a lower cost.

Abstract: A material containing a flavonoid glycoside represented by formula I as a major component has an in vivo antiallergic effect, which can be prepared in a large amount with a lower cost.